GlassScriptPhysician profile
Savannah Wagoner
NPI 1295433241
$2,292.65
in general payments reported to CMS, 2019-2025
17 companies · $201 in 2025
The $201 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $502 · 2024: $1,590 · 2025: $201.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,218 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,217.66 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $570.01 | 2023-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $380.70 | 2023-2024 | Zepbound, Mounjaro, Emgality |
| Abbvie INC. | $331.79 | 2024 | |
| Novo Nordisk INC | $206.23 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $151.27 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Astellas Pharma US INC | $150.77 | 2023-2024 | Veozah |
| Amgen INC. | $86.49 | 2024 | Repatha, Otezla |
| Pfizer INC. | $80.84 | 2024-2025 | |
| Lundbeck LLC | $71.21 | 2024 | Rexulti |
| Exact Sciences Corporation | $56.25 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56.14 | 2023-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $38.22 | 2024 | Trintellix |
| Azurity Pharmaceuticals, INC. | $32.50 | 2023 | Horizant |
| Bausch Health US, LLC | $29.91 | 2023-2024 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $21.17 | 2024 | Auvelity |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $15.15 | 2024 | Injectafer |
| Indivior INC. | $14.00 | 2024 | Sublocade |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Savannah Wagoner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.